PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8114080-5	1993	This conclusion is supported by the following observations: (i) RVD response is blocked selectively by the phospholipase A2 inhibitors manoalide and bromophenacyl-bromide (0.2 and 5 microM, respectively) but not by phospholipase C inhibitors.	manoalide	135-144	phospholipase A2 group IB	Homo sapiens	107-123
8106442-2	1994	Monocyte Chemotactic Protein-1 (MCP-1), a member of the Cys-Cys branch of the chemokine superfamily, induced a mepacrine- and manoalide-sensitive increase in the release of [3H]arachidonic acid from prelabeled human monocytes and monocytic THP-1 leukemic cells.	manoalide	126-135	C-C motif chemokine ligand 2	Homo sapiens	0-30
8106442-2	1994	Monocyte Chemotactic Protein-1 (MCP-1), a member of the Cys-Cys branch of the chemokine superfamily, induced a mepacrine- and manoalide-sensitive increase in the release of [3H]arachidonic acid from prelabeled human monocytes and monocytic THP-1 leukemic cells.	manoalide	126-135	C-C motif chemokine ligand 2	Homo sapiens	32-37
8106442-8	1994	Phospholipase A2 inhibitors (mepacrine, p-bromophenacyl bromide, and manoalide) blocked monocyte polarization and chemotaxis induced by MCP-1.	manoalide	69-78	phospholipase A2 group IB	Homo sapiens	0-16
8106442-8	1994	Phospholipase A2 inhibitors (mepacrine, p-bromophenacyl bromide, and manoalide) blocked monocyte polarization and chemotaxis induced by MCP-1.	manoalide	69-78	C-C motif chemokine ligand 2	Homo sapiens	136-141
8250938-1	1993	The phospholipase A2 (PLA2) inhibitors quinacrine, manoalide and scalaradial inhibit the carbachol-stimulated secretion of the amyloid precursor protein (APP) from cells transfected with the human m1 muscarinic receptor.	manoalide	51-60	phospholipase A2 group IB	Homo sapiens	4-20
8250938-1	1993	The phospholipase A2 (PLA2) inhibitors quinacrine, manoalide and scalaradial inhibit the carbachol-stimulated secretion of the amyloid precursor protein (APP) from cells transfected with the human m1 muscarinic receptor.	manoalide	51-60	phospholipase A2 group IB	Homo sapiens	22-26
8250938-1	1993	The phospholipase A2 (PLA2) inhibitors quinacrine, manoalide and scalaradial inhibit the carbachol-stimulated secretion of the amyloid precursor protein (APP) from cells transfected with the human m1 muscarinic receptor.	manoalide	51-60	amyloid beta precursor protein	Homo sapiens	127-152
8228253-3	1993	The selective inhibition of PLA2 by the marine natural products manoalide (MLD) and scalaradial (SLD) blocks [3H]arachidonic acid (AA) release in calcium ionophore A23187-stimulated neutrophils, and also inhibits secretion of specific and azurophilic granule constituents.	manoalide	64-73	phospholipase A2 group IB	Homo sapiens	28-32
1294693-4	1992	Examples of marine natural products that inhibit PLA2 are manoalide and its derivatives, scalaradial and related compounds, the pseudopterosins, the vidalols, and a group of terpenoids that contain masked 1,4-dicarbonyl moieties.	manoalide	58-67	phospholipase A2 group IB	Homo sapiens	49-53
8515424-0	1993	Molecular model of the interaction of bee venom phospholipase A2 with manoalide.	manoalide	70-79	phospholipase A2 group IB	Homo sapiens	48-64
8515424-1	1993	A molecular model of the interaction between manoalide (MLD) and bee venom phospholipase A2 (bv-PLA2) has been derived making use of a combination of computational methods.	manoalide	45-54	phospholipase A2 group IB	Homo sapiens	75-91
8515424-1	1993	A molecular model of the interaction between manoalide (MLD) and bee venom phospholipase A2 (bv-PLA2) has been derived making use of a combination of computational methods.	manoalide	45-54	phospholipase A2 group IIA	Homo sapiens	96-100
8496167-6	1993	Addition of phospholipase A2 (PLA2) inhibitors (quinacrine, 4-bromophenacyl bromide, manoalide) to the perfusion medium inhibited K(+)-stimulated [3H]ACh and [3H]AA release in a dose-dependent manner.	manoalide	85-94	phospholipase A2 group IB	Rattus norvegicus	12-28
8496167-6	1993	Addition of phospholipase A2 (PLA2) inhibitors (quinacrine, 4-bromophenacyl bromide, manoalide) to the perfusion medium inhibited K(+)-stimulated [3H]ACh and [3H]AA release in a dose-dependent manner.	manoalide	85-94	phospholipase A2 group IB	Rattus norvegicus	30-34
8461044-6	1993	The addition of the phospholipase A2 inhibitors manoalide, mepacrine, or U-26384, or the phospholipase C inhibitor U-73122, reduced the severity of cell injury, but did not maintain cell viability.	manoalide	48-57	phospholipase A2 group IB	Homo sapiens	20-36
1885583-2	1991	We have previously described the irreversible inhibition of cobra venom phospholipase A2 (PLA2) by the marine natural product manoalide (MLD) (Lombardo, D., and Dennis, E. A.	manoalide	126-135	phospholipase A2 group IB	Homo sapiens	72-88
1324685-10	1992	The present data are discussed in relation to the proposed model for PLA2 inactivation by manoalide.	manoalide	90-99	phospholipase A2 group IB	Homo sapiens	69-73
1885583-2	1991	We have previously described the irreversible inhibition of cobra venom phospholipase A2 (PLA2) by the marine natural product manoalide (MLD) (Lombardo, D., and Dennis, E. A.	manoalide	126-135	phospholipase A2 group IB	Homo sapiens	90-94
35252186-0	2022	Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis.	manoalide	51-60	NLR family, pyrin domain containing 3	Mus musculus	18-23
2337412-3	1990	These kinetic parameters were utilized subsequently to evaluate the inhibitory effects of manoalide on HSF-PLA2.	manoalide	90-99	interleukin 6	Homo sapiens	103-106
2337412-3	1990	These kinetic parameters were utilized subsequently to evaluate the inhibitory effects of manoalide on HSF-PLA2.	manoalide	90-99	phospholipase A2 group IIA	Homo sapiens	107-111
1793057-6	1991	A reported PLA2 inhibitor, manoalide, was a potent inhibitor of PLA2 in both assay systems.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	11-15
1793057-6	1991	A reported PLA2 inhibitor, manoalide, was a potent inhibitor of PLA2 in both assay systems.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	64-68
2268367-0	1990	Inhibition by manoalide of fMLP-stimulated elastase release from human neutrophils.	manoalide	14-23	formyl peptide receptor 1	Homo sapiens	27-31
2268367-3	1990	To understand the mechanism of this inhibition, we examined the effect of manoalide on the signal-transduction pathway believed to mediate fMLP stimulation.	manoalide	74-83	formyl peptide receptor 1	Homo sapiens	139-143
2268367-4	1990	We observed in fura-2 loaded cells that pretreatment with manoalide blocked fMLP-induced increases in cytosolic free-calcium (IC50 approximately 0.15 microM).	manoalide	58-67	formyl peptide receptor 1	Homo sapiens	76-80
35252186-2	2022	Through screening the small molecule library, we found that manoalide is a highly selective small molecule inhibitor of NLRP3.	manoalide	60-69	NLR family, pyrin domain containing 3	Mus musculus	120-125
35252186-3	2022	Mechanismly, manoalide inhibited the NLRP3 inflammasome activation by acting downstream of potassium efflux, chloride efflux and mitochondrial dysfunction.	manoalide	13-22	NLR family, pyrin domain containing 3	Mus musculus	37-42
35252186-4	2022	Moreover, manoalide blocked the interaction between NEK7 and NLRP3 by covalently binding to Lys 377 of the NLRP3 protein.	manoalide	10-19	NIMA (never in mitosis gene a)-related expressed kinase 7	Mus musculus	52-56
35252186-4	2022	Moreover, manoalide blocked the interaction between NEK7 and NLRP3 by covalently binding to Lys 377 of the NLRP3 protein.	manoalide	10-19	NLR family, pyrin domain containing 3	Mus musculus	61-66
35252186-4	2022	Moreover, manoalide blocked the interaction between NEK7 and NLRP3 by covalently binding to Lys 377 of the NLRP3 protein.	manoalide	10-19	NLR family, pyrin domain containing 3	Mus musculus	107-112
35252186-6	2022	Thus, our results identify manoalide as a selective and covalent NLRP3 inhibitor and suggest it has the potential for the treatment of NLRP3-associated diseases.	manoalide	27-36	NLR family, pyrin domain containing 3	Mus musculus	65-70
35252186-6	2022	Thus, our results identify manoalide as a selective and covalent NLRP3 inhibitor and suggest it has the potential for the treatment of NLRP3-associated diseases.	manoalide	27-36	NLR family, pyrin domain containing 3	Mus musculus	135-140
2640487-0	1989	[Manoalide: a new phospholipase A2 inhibitor of marine origin with potential immunoregulatory effect].	manoalide	1-10	phospholipase A2, group IB, pancreas	Mus musculus	18-34
2586492-0	1989	Manoalide: structure-activity studies and definition of the pharmacophore for phospholipase A2 inactivation.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	78-94
2586492-1	1989	Manoalide is a potent antiinflammatory marine natural product and a direct inactivator of venom phospholipase A2 (PLA2; EC 3.1.1.4).	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	96-112
2586492-1	1989	Manoalide is a potent antiinflammatory marine natural product and a direct inactivator of venom phospholipase A2 (PLA2; EC 3.1.1.4).	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	114-118
2586492-2	1989	Manoalide has been shown to irreversibly inhibit PLA2, with the corresponding modification of a selective number of lysine residues.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	49-53
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	140-149	phospholipase A2 group IB	Homo sapiens	244-248
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	140-149	phospholipase A2 group IB	Homo sapiens	373-377
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	229-238	phospholipase A2 group IB	Homo sapiens	244-248
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	229-238	phospholipase A2 group IB	Homo sapiens	373-377
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	229-238	phospholipase A2 group IB	Homo sapiens	244-248
2586492-4	1989	These studies indicate that 1) the presence of the hemiacetal in the alpha-hydroxydihydropyran ring is required for irreversible binding of manoalide, 2) the gamma-hydroxybutenolide ring is involved in the initial interaction of manoalide with PLA2, and 3) the hydrophobic nature of the trimethylcyclohexenyl ring system allows nonbonded interactions between manoalide and PLA2 that enhance the potency of these analogs.	manoalide	229-238	phospholipase A2 group IB	Homo sapiens	373-377
2586492-5	1989	These structure-activity relationship studies suggest that the closed ring form of manoalide is the predominant molecular species that accounts for the selective and potent inhibition of PLA2 by manoalide.	manoalide	83-92	phospholipase A2 group IB	Homo sapiens	187-191
2586492-5	1989	These structure-activity relationship studies suggest that the closed ring form of manoalide is the predominant molecular species that accounts for the selective and potent inhibition of PLA2 by manoalide.	manoalide	195-204	phospholipase A2 group IB	Homo sapiens	187-191
2707379-4	1989	Luffolide (4) has some of the anti-inflammatory properties of manoalide (1): this may help to define the chemical reaction between manoalide (1) and phospholipase A2.	manoalide	62-71	phospholipase A2 group IB	Homo sapiens	149-165
2707379-4	1989	Luffolide (4) has some of the anti-inflammatory properties of manoalide (1): this may help to define the chemical reaction between manoalide (1) and phospholipase A2.	manoalide	131-140	phospholipase A2 group IB	Homo sapiens	149-165
2498315-7	1989	Manoalide and its analog, manoalogue, were found to be good inhibitors of the P388D1 PLA2 (IC50 = 16 and 26 microM, respectively).	manoalide	0-9	phospholipase A2, group IB, pancreas	Mus musculus	85-89
2498315-12	1989	Manoalide, manoalogue, and 7,7-dimethyl-5,8-eicosadienoic acid, effective inhibitors of the isolated PLA2, inhibited PGE2 production in intact P388D1 cells 40-85% in the concentration range studied.	manoalide	0-9	phospholipase A2, group IB, pancreas	Mus musculus	101-105
2640487-2	1989	Manoalide inhibits phospholipase A2 from extracellular sources (snake venoms, bee, etc.	manoalide	0-9	phospholipase A2	Oryctolagus cuniculus	19-35
2640487-9	1989	Since it has been shown that eicosanoids have immunoregulatory functions, a future possibility is that a phospholipase A2 inhibitor such as Manoalide may prove useful to investigate the biological role of eicosanoid metabolites on the immune function.	manoalide	140-149	phospholipase A2, group IB, pancreas	Mus musculus	105-121
2840081-0	1988	Preferential inhibition of 5-lipoxygenase activity by manoalide.	manoalide	54-63	arachidonate 5-lipoxygenase	Homo sapiens	27-41
3178877-0	1988	Inactivation of phospholipase A2 by manoalide.	manoalide	36-45	phospholipase A2 group IB	Homo sapiens	16-32
3178877-1	1988	Localization of the manoalide binding site on bee venom phospholipase A2.	manoalide	20-29	phospholipase A2 group IB	Homo sapiens	56-72
3178877-2	1988	The marine natural product manoalide (MLD), a potent inhibitor of phospholipases, completely inactivates bee venom phospholipase A2 (PLA2) by an irreversible mechanism.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	115-131
3178877-2	1988	The marine natural product manoalide (MLD), a potent inhibitor of phospholipases, completely inactivates bee venom phospholipase A2 (PLA2) by an irreversible mechanism.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	133-137
2840081-3	1988	In RBL-1 cells, manoalide inhibited 5-lipoxygenase (5-LO) activity with an approximate IC50 of 0.3 microM.	manoalide	16-25	arachidonate 5-lipoxygenase	Homo sapiens	36-50
2840081-6	1988	Manoalide showed some activity against soybean lipoxygenase, although it was 30- to 50-fold less potent than as an inhibitor of the 5-lipoxygenase enzyme.	manoalide	0-9	linoleate 9S-lipoxygenase-4	Glycine max	47-59
2437121-3	1987	In A431 cells the increase in epidermal growth factor receptor-mediated Ca2+ entry and release from intracellular Ca2+ stores were blocked by manoalide in a time-dependent manner with an IC50 of 0.4 microM.	manoalide	142-151	epidermal growth factor like 1	Rattus norvegicus	30-53
2827828-0	1987	The inhibition of release of endothelium-derived relaxant factor by manoalide, a potent inhibitor of phospholipase A2.	manoalide	68-77	phospholipase A2	Oryctolagus cuniculus	101-117
3343241-9	1988	The lyophilized preparation of the enzyme is routinely purified about 60-fold and is suitable for evaluating phospholipase A2 inhibitors such as manoalide analogues.	manoalide	145-154	phospholipase A2, group IB, pancreas	Mus musculus	109-125
3150849-1	1988	The marine natural produce manoalide has been reported to inactivate venom phospholipase A2 from several sources and phospholipase A2 from polymorphonuclear leukocytes.	manoalide	27-36	phospholipase A2, group IB, pancreas	Mus musculus	75-91
3150849-1	1988	The marine natural produce manoalide has been reported to inactivate venom phospholipase A2 from several sources and phospholipase A2 from polymorphonuclear leukocytes.	manoalide	27-36	phospholipase A2, group IB, pancreas	Mus musculus	117-133
3203166-1	1988	Manoalide (MND), a sesterterpenoid first isolated from the marine sponge Luffariela variabilis and later synthesized by Japanese chemists, exhibits anti-inflammatory activity and directly inactivates bee and snake venom phospholipase A2.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	220-236
2437121-5	1987	In GH# cells, manoalide blocked the thyrotropin-releasing hormone-dependent release of Ca2+ from intracellular stores without inhibition of the formation of inositol phosphates from phosphatidylinositol 4,5-bisphosphate.	manoalide	14-23	thyrotropin releasing hormone	Rattus norvegicus	36-65
3103628-1	1987	Manoalide, a novel nonsteroidal sesterterpenoid, is a potent inhibitor of phospholipase A2 isolated from bee and cobra venoms.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	74-90
3103628-2	1987	This report compares the inhibition by manoalide of phospholipase A2 in crude cytosol fractions from four mammalian tissues with that of four purified extracellular phospholipase A2"s.	manoalide	39-48	phospholipase A2 group IB	Homo sapiens	52-68
3103628-3	1987	Phospholipase A2 isolated from bee venom (Apis mellifera) was the most sensitive to inactivation by manoalide (IC50 approximately equal to 0.12 microM).	manoalide	100-109	phospholipase A2	Apis mellifera	0-16
3103628-4	1987	Extracellular phospholipase A2 from rattlesnake and cobra venom was intermediate in sensitivity to manoalide (IC50 values of 0.7 and 1.9 microM respectively).	manoalide	99-108	phospholipase A2 group IB	Homo sapiens	14-30
3103628-5	1987	Porcine pancreatic phospholipase A2 was relatively resistant to inactivation by manoalide (IC50 approximately equal to 30 microM).	manoalide	80-89	phospholipase A2 group IB	Homo sapiens	19-35
3103628-7	1987	Cytosolic proteins as well as bovine serum albumin and poly-L-lysine (Mr = 57,000) protected purified bee venom phospholipase A2 from inactivation by manoalide.	manoalide	150-159	phospholipase A2 group IB	Homo sapiens	112-128
3103628-10	1987	These data suggest that lysine is capable of reacting with manoalide, but only when it is present in macromolecules is it capable of protecting phospholipase A2 from inactivation by manoalide.	manoalide	182-191	phospholipase A2 group IB	Homo sapiens	144-160
3103628-11	1987	Because cellular proteins protect PLA2 from inactivation by manoalide, high concentrations of manoalide must be applied topically to produce statistically significant inactivation of intracellular phospholipase A2.	manoalide	94-103	phospholipase A2 group IIA	Homo sapiens	34-38
3103628-11	1987	Because cellular proteins protect PLA2 from inactivation by manoalide, high concentrations of manoalide must be applied topically to produce statistically significant inactivation of intracellular phospholipase A2.	manoalide	94-103	phospholipase A2 group IB	Homo sapiens	197-213
3801502-0	1987	The inhibition of phospholipase A2 by manoalide and manoalide analogues.	manoalide	38-47	phospholipase A2 group IB	Homo sapiens	18-34
3801502-0	1987	The inhibition of phospholipase A2 by manoalide and manoalide analogues.	manoalide	52-61	phospholipase A2 group IB	Homo sapiens	18-34
3801502-2	1987	Previous work has shown that manoalide is also a potent covalent inhibitor of the extracellular phospholipase A2 from cobra venom and that the inhibition correlated with a pH-dependent change in manoalide (Lombardo and Dennis (1985) J. Biol.	manoalide	29-38	phospholipase A2 group IB	Homo sapiens	96-112
3801502-6	1987	The cobra venom phospholipase A2 may be able to catalyze the opening or isomerization of one of these rings, raising the possibility that manoalide is acting as a suicide substrate.	manoalide	138-147	phospholipase A2 group IB	Homo sapiens	16-32
3997864-0	1985	Cobra venom phospholipase A2 inhibition by manoalide.	manoalide	43-52	phospholipase A2 group IB	Homo sapiens	12-28
3111475-0	1987	Inactivation of bee venom phospholipase A2 by manoalide.	manoalide	46-55	phospholipase A2 group IB	Homo sapiens	26-42
3111475-2	1987	The marine natural product manoalide (MLD), a potent irreversible inhibitor of bee venom phospholipase A2 (PLA2), was shown to produce a chromophore (lambda max = 437 nm) during incubation with the enzyme.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	89-105
3111475-2	1987	The marine natural product manoalide (MLD), a potent irreversible inhibitor of bee venom phospholipase A2 (PLA2), was shown to produce a chromophore (lambda max = 437 nm) during incubation with the enzyme.	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	107-111
2437121-1	1987	Manoalide is a marine natural product that has anti-inflammatory and anti-proliferative activities and is an irreversible inhibitor of phospholipase A2 and phospholipase C.	manoalide	0-9	phospholipase A2 group IB	Rattus norvegicus	135-171
3026352-6	1986	Release of arachidonic acid is probably via phospholipase A2, since it is blocked by the phospholipase A2 inhibitor manoalide.	manoalide	116-125	phospholipase A2	Oryctolagus cuniculus	44-60
3026352-6	1986	Release of arachidonic acid is probably via phospholipase A2, since it is blocked by the phospholipase A2 inhibitor manoalide.	manoalide	116-125	phospholipase A2	Oryctolagus cuniculus	89-105
3947381-2	1986	The marine natural product manoalide (MLD) was shown to directly inactivate bee venom phospholipase A2 (PLA2).	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	86-102
3947381-2	1986	The marine natural product manoalide (MLD) was shown to directly inactivate bee venom phospholipase A2 (PLA2).	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	104-108
3997864-2	1985	Manoalide, an unusual nonsteroidal sesterterpenoid recently isolated from sponge, antagonizes phorbol-induced inflammation but not that induced by arachidonic acid, suggesting that manoalide acts prior to the cyclooxygenase step in prostaglandin synthesis, possibly by inhibiting phospholipase A2.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	280-296
3997864-3	1985	We have now studied the inhibitory effect of manoalide on a homogeneous preparation of phospholipase A2 from cobra venom.	manoalide	45-54	phospholipase A2 group IB	Homo sapiens	87-103
3997864-4	1985	For a given concentration of manoalide, the inhibition of phospholipase A2 activity toward dipalmitoylphosphatidylcholine/Triton X-100 mixed micelles is time-dependent and plateaus at about 85% inhibition of the initial velocity even after extensive preincubation.	manoalide	29-38	phospholipase A2 group IB	Homo sapiens	58-74
3997864-7	1985	Under typical conditions (20-min preincubation, 40 degrees C, pH 7.1), 50% inhibition is achieved at a manoalide concentration of about 2 X 10(-6) M. The data indicate that manoalide is a potent inhibitor of the cobra venom phospholipase A2.	manoalide	103-112	phospholipase A2 group IB	Homo sapiens	224-240
3997864-7	1985	Under typical conditions (20-min preincubation, 40 degrees C, pH 7.1), 50% inhibition is achieved at a manoalide concentration of about 2 X 10(-6) M. The data indicate that manoalide is a potent inhibitor of the cobra venom phospholipase A2.	manoalide	173-182	phospholipase A2 group IB	Homo sapiens	224-240
31487907-3	2019	MTS assay at 24 h showed that manoalide inhibited the proliferation of six types of oral cancer cell lines (SCC9, HSC3, OC2, OECM-1, Ca9-22, and CAL 27) but did not affect the proliferation of normal oral cell line (human gingival fibroblasts (HGF-1)).	manoalide	30-39	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	114-118
6468604-2	1984	Manoalide was also found to inactivate purified phospholipase A2 and thus prevent hydrolysis of phosphatidylcholine.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	48-64
31487907-3	2019	MTS assay at 24 h showed that manoalide inhibited the proliferation of six types of oral cancer cell lines (SCC9, HSC3, OC2, OECM-1, Ca9-22, and CAL 27) but did not affect the proliferation of normal oral cell line (human gingival fibroblasts (HGF-1)).	manoalide	30-39	one cut homeobox 2	Homo sapiens	120-123
31487907-6	2019	Manoalide also induces more annexin V expression in oral cancer Ca9-22 and CAL 27 cells than that of HGF-1 cells.	manoalide	0-9	annexin A5	Homo sapiens	28-37
31487907-7	2019	Manoalide induces activation of caspase 3 (Cas 3), which is a hallmark of apoptosis in oral cancer cells, Ca9-22 and CAL 27.	manoalide	0-9	caspase 3	Homo sapiens	32-41
31487907-7	2019	Manoalide induces activation of caspase 3 (Cas 3), which is a hallmark of apoptosis in oral cancer cells, Ca9-22 and CAL 27.	manoalide	0-9	caspase 3	Homo sapiens	43-48
31487907-8	2019	Inhibitors of Cas 8 and Cas 9 suppress manoalide-induced Cas 3 activation.	manoalide	39-48	caspase 3	Homo sapiens	57-62
22394195-0	2012	Inhibition of hepatitis C virus NS3 helicase by manoalide.	manoalide	48-57	KRAS proto-oncogene, GTPase	Homo sapiens	32-35
22209310-6	2013	Phospholipase A2 (PLA2) inhibitor (manoalide) and cytosolic PLA2 (cPLA2) inhibitor (arachidonyltrifluoromenthylketone [AACOCF3]) more strongly attenuated contraction in SAH (1 hour and 1 week) than in controls.	manoalide	35-44	phospholipase A2 group IB	Rattus norvegicus	0-16
22394195-8	2012	Manoalide (1) also has the ability to inhibit the ATPase activity of human DHX36/RHAU, a putative RNA helicase.	manoalide	0-9	dynein axonemal heavy chain 8	Homo sapiens	50-56
22394195-8	2012	Manoalide (1) also has the ability to inhibit the ATPase activity of human DHX36/RHAU, a putative RNA helicase.	manoalide	0-9	DEAH-box helicase 36	Homo sapiens	75-80
22394195-8	2012	Manoalide (1) also has the ability to inhibit the ATPase activity of human DHX36/RHAU, a putative RNA helicase.	manoalide	0-9	DEAH-box helicase 36	Homo sapiens	81-85
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	mitogen-activated protein kinase 3	Mus musculus	184-190
22359435-5	2012	Besides marine natural products that inhibit PLA(2) are manoalide and its derivatives such as scalaradial and related compounds, pseudopterosins and vidalols, tetracylne from synthetic chemicals etc.	manoalide	56-65	phospholipase A2 group IB	Homo sapiens	45-51
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	195-202
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	toll-like receptor 12	Mus musculus	207-213
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	toll-like receptor 2	Mus musculus	215-219
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	toll-like receptor 3	Mus musculus	221-225
19265167-6	2009	Furthermore, inhibition of sPLA(2)-V by RNA interference or by two cell-permeable compounds, namely scalaradial and manoalide, resulted in a marked reduction of the phosphorylation of ERK1/2 and cPLA(2) via TLR1/2, TLR2, TLR3, and TLR4, leading to attenuated AA mobilization.	manoalide	116-125	toll-like receptor 4	Mus musculus	231-235
16406345-4	2006	Treatment with the PLA2 inhibitor, manoalide, blocked the release of oxoM (muscarinic receptor agonist)-stimulated sAPPalpha, and the muscarinic receptor-mediated sAPPalpha release was increased by the non-selective PLA2 activator mellitin.	manoalide	35-44	phospholipase A2 group IB	Homo sapiens	19-23
17537804-2	2007	The taurine release is potentiated by H(2)O(2) and the tyrosine phosphatase inhibitor vanadate and reduced by the phospholipase A(2) (PLA(2)) inhibitors bromoenol lactone (BEL) and manoalide, the 5-lipoxygenase (5-LO) inhibitor ETH-615139, the NADPH oxidase inhibitor diphenyl iodonium (DPI), and antioxidants.	manoalide	181-190	phospholipase A2, group IB, pancreas	Mus musculus	114-132
17537804-2	2007	The taurine release is potentiated by H(2)O(2) and the tyrosine phosphatase inhibitor vanadate and reduced by the phospholipase A(2) (PLA(2)) inhibitors bromoenol lactone (BEL) and manoalide, the 5-lipoxygenase (5-LO) inhibitor ETH-615139, the NADPH oxidase inhibitor diphenyl iodonium (DPI), and antioxidants.	manoalide	181-190	phospholipase A2, group IB, pancreas	Mus musculus	134-140
17691073-1	2007	Several marine terpenoids that contain at least one reactive aldehyde group, such as manoalide and its congeners, possess interesting anti-inflammatory activities that are mediated by the covalent inactivation of secretory phospholipase A(2) (sPLA(2)).	manoalide	85-94	phospholipase A2 group IIA	Homo sapiens	213-241
17691073-1	2007	Several marine terpenoids that contain at least one reactive aldehyde group, such as manoalide and its congeners, possess interesting anti-inflammatory activities that are mediated by the covalent inactivation of secretory phospholipase A(2) (sPLA(2)).	manoalide	85-94	phospholipase A2 group IIA	Homo sapiens	243-250
16406345-4	2006	Treatment with the PLA2 inhibitor, manoalide, blocked the release of oxoM (muscarinic receptor agonist)-stimulated sAPPalpha, and the muscarinic receptor-mediated sAPPalpha release was increased by the non-selective PLA2 activator mellitin.	manoalide	35-44	phospholipase A2 group IB	Homo sapiens	216-220
15792359-12	2005	Manoalide, a specific inhibitor of sPLA2, completely blocked the LPC accumulation.	manoalide	0-9	phospholipase A2 group IIA	Homo sapiens	35-40
16120751-6	2005	PCB 50-induced release of AA from RMC was also attenuated with the PLA2-specific inhibitors methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL), and manoalide (p < 0.05).	manoalide	166-175	pyruvate carboxylase	Rattus norvegicus	0-3
16120751-6	2005	PCB 50-induced release of AA from RMC was also attenuated with the PLA2-specific inhibitors methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL), and manoalide (p < 0.05).	manoalide	166-175	phospholipase A2 group IB	Rattus norvegicus	67-71
16164449-12	2005	Calphostin C, wortmannin and manoalide attenuated CD62L down-regulation, suggesting the potential implication of protein kinase C, phosphatidylinositol 3-kinase and phospholipase A(2) in the process.	manoalide	29-38	selectin L	Homo sapiens	50-55
16164449-12	2005	Calphostin C, wortmannin and manoalide attenuated CD62L down-regulation, suggesting the potential implication of protein kinase C, phosphatidylinositol 3-kinase and phospholipase A(2) in the process.	manoalide	29-38	phospholipase A2 group IB	Homo sapiens	165-182
10729747-0	2000	Simultaneous inhibition of renal phospholipase A(2) and glutathione synthesis by manoalide and DL-buthionine sulfoximine induces acute tubular dysfunction in rats.	manoalide	81-90	phospholipase A2 group IB	Rattus norvegicus	33-51
12963645-9	2003	Inhibition of other PLA2 isoforms, secretory PLA2 and calcium-independent PLA2, by manoalide and haloenol-lactone suicide substrate, respectively, does not affect this effect of AGEs relative to inhibitor-treated controls.	manoalide	83-92	phospholipase A2 group IIA	Homo sapiens	20-24
12325001-7	2002	Similar results in terms of the reaction profile, mass increments, and location of the PLA(2) binding site were obtained for manoalide, a paradigm for irreversible PLA(2) inhibitors, which suggests that the present results may be considered of more general interest within the field of anti-inflammatory sesterterpenes that contain the gamma-hydroxybutenolide pharmacophore.	manoalide	125-134	phospholipase A2 group IB	Homo sapiens	87-93
12325001-7	2002	Similar results in terms of the reaction profile, mass increments, and location of the PLA(2) binding site were obtained for manoalide, a paradigm for irreversible PLA(2) inhibitors, which suggests that the present results may be considered of more general interest within the field of anti-inflammatory sesterterpenes that contain the gamma-hydroxybutenolide pharmacophore.	manoalide	125-134	phospholipase A2 group IB	Homo sapiens	164-170
11992645-0	2002	Inhibition of crotoxin phospholipase A(2) activity by manoalide associated with inactivation of crotoxin toxicity and dissociation of the heterodimeric neurotoxic complex.	manoalide	54-63	phospholipase A2 group IB	Rattus norvegicus	23-41
11992645-3	2002	We, thus, studied the effect of manoalide (MLD), a PLA(2) inhibitor, on the toxin catalytic activity and its central and peripheral toxicity.	manoalide	32-41	phospholipase A2 group IB	Rattus norvegicus	51-57
11060901-4	2000	N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), a PAF synthesis inhibitor, and manoalide, a phospholipase A2 inhibitor, reduced 12(R)-HETE-induced [Ca2+]i rise.	manoalide	83-92	phospholipase A2 group IB	Homo sapiens	96-112
15107407-4	2004	Phospholipase A(2) inhibition with manoalide significantly decreased O(2)(*-) release.	manoalide	35-44	phospholipase A2 group IB	Rattus norvegicus	0-17
11799199-8	2002	The enzyme activity of the VP1 unique region showed typical Ca(2+) dependency and could be inhibited by manoalide and 4-bromophenacylbromide, which bind covalently to lysine and histidine residues, respectively, as part of the active center of the enzyme.	manoalide	104-113	capsid protein 1	Human parvovirus B19	27-30
11226404-4	2001	Phospholipase A(2) inhibitors, manoalide (0.1--10 microM) and oleyloxyethyl phosphorylcholine (1--10 microM), significantly inhibited ethanol-induced contraction.	manoalide	31-40	phospholipase A2 group IB	Homo sapiens	0-18
10762671-7	2000	The augmentation of the acetylcholine concentration-response curves for muscle tension in the presence of TNF-alpha (10 ng/ml) was inhibited in part after application of manoalide, a phospholipase A(2) inhibitor.	manoalide	170-179	tumor necrosis factor	Bos taurus	106-115
10762671-7	2000	The augmentation of the acetylcholine concentration-response curves for muscle tension in the presence of TNF-alpha (10 ng/ml) was inhibited in part after application of manoalide, a phospholipase A(2) inhibitor.	manoalide	170-179	LOC104974671	Bos taurus	183-200
10729747-7	2000	In contrast, the activity of PLA(2) in renal tissue decreased in the group that received both BSO and manoalide as compared with the groups that received BSO alone or physiological saline.	manoalide	102-111	phospholipase A2 group IB	Rattus norvegicus	29-35
10410383-3	1999	Treatment with drugs that inhibit AA mobilization such as dexamethasone or manoalide or inhibitors of leukotriene formation such as zileuton or baicalein, reduced TPA-induced edema development and PGHS-2 levels.	manoalide	75-84	prostaglandin-endoperoxide synthase 2	Mus musculus	197-203
10757711-3	2000	All compounds significantly inhibited human synovial phospholipase A(2) (PLA(2)) at 10 microM, with an IC(50) value of 5.8 microM for compound 4, which is the most potent inhibitor, with a higher selectivity toward this enzyme than the reference inhibitor manoalide.	manoalide	256-265	phospholipase A2 group IB	Homo sapiens	73-79
10101221-2	1999	The antiinflammatory activity of manoalide is due to inhibition of PLA2, through irreversible binding to several lysine residues.	manoalide	33-42	phospholipase A2 group IB	Homo sapiens	67-71
10101221-5	1999	It appears that the minimum structural requirement for exhibiting manoalide-like PLA2 inhibition would be the presence in the inhibitor of functional groups able to seize the amino groups of PLA2 lysine residues with formation of stable covalent bonds.	manoalide	66-75	phospholipase A2 group IB	Homo sapiens	81-85
10101221-5	1999	It appears that the minimum structural requirement for exhibiting manoalide-like PLA2 inhibition would be the presence in the inhibitor of functional groups able to seize the amino groups of PLA2 lysine residues with formation of stable covalent bonds.	manoalide	66-75	phospholipase A2 group IB	Homo sapiens	191-195
10101221-6	1999	Many manoalide analogues have been isolated from marine sponges, most of them sharing PLA2 inhibitory properties.	manoalide	5-14	phospholipase A2 group IB	Homo sapiens	86-90
10215694-4	1999	Pretreatment of uterine strips with the PLA2 inhibitor (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one (HELSS) or manoalide, or an inhibitor of the G protein of PLA2, isotetrandrine, completely prevented the increase of contractile frequency induced by 50 microM A1242.	manoalide	133-142	phospholipase A2 group IB	Rattus norvegicus	40-44
10087000-1	1999	The marine product petrosaspongiolide M is a novel inhibitor of phospholipase A2 (PLA2), showing selectivity for secretory PLA2 versus cytosolic PLA2, with a potency on the human synovial enzyme (group II) similar to that of manoalide.	manoalide	225-234	phospholipase A2 group IB	Homo sapiens	64-80
10087000-1	1999	The marine product petrosaspongiolide M is a novel inhibitor of phospholipase A2 (PLA2), showing selectivity for secretory PLA2 versus cytosolic PLA2, with a potency on the human synovial enzyme (group II) similar to that of manoalide.	manoalide	225-234	phospholipase A2 group IB	Homo sapiens	82-86
10087000-2	1999	This compound was more potent than manoalide on bee venom PLA2 (group III) and had no effect on group I enzymes (Naja naja and porcine pancreatic PLA2).	manoalide	35-44	phospholipase A2, group IB, pancreas	Mus musculus	58-62
10437157-1	1999	AIM: To study effect of manoalide on apoptosis induced by deprivation of acidic fibroblast growth factor (aFGF) and serum in vascular endothelial cells (VEC).	manoalide	24-33	fibroblast growth factor 1	Homo sapiens	73-104
10437157-1	1999	AIM: To study effect of manoalide on apoptosis induced by deprivation of acidic fibroblast growth factor (aFGF) and serum in vascular endothelial cells (VEC).	manoalide	24-33	fibroblast growth factor 1	Homo sapiens	106-110
10051149-3	1999	In in vitro studies, this compound inhibited phospholipase A2 (PLA2), showing selectivity for secretory PLA2 (sPLA2) versus cytosolic PLA2 (cPLA2), and its potency on the human synovial enzyme (group II) was similar to that of manoalide.	manoalide	227-236	phospholipase A2 group IB	Homo sapiens	45-61
10051149-3	1999	In in vitro studies, this compound inhibited phospholipase A2 (PLA2), showing selectivity for secretory PLA2 (sPLA2) versus cytosolic PLA2 (cPLA2), and its potency on the human synovial enzyme (group II) was similar to that of manoalide.	manoalide	227-236	phospholipase A2 group IB	Homo sapiens	63-67
9506261-9	1998	Both Zn(2+)- and ZnO-induced CL was inhibited by manoalide, a phospholipase A2 inhibitor, with IC50 of 0.25 microM and 0.66 microM respectively.	manoalide	49-58	phospholipase A2 group IB	Homo sapiens	62-78
9804280-0	1998	Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat.	manoalide	0-9	phospholipase A2 group IB	Rattus norvegicus	13-29
9804280-6	1998	Calcium-independent phospholipase A2 activity in brain homogenate was reduced by manoalide, whereas phospholipase C activity was unaffected.	manoalide	81-90	phospholipase A2 group IB	Rattus norvegicus	20-36
9804280-9	1998	This study indicates that manoalide can be used to inhibit brain phospholipase A2 in vivo, and that phospholipase A2 plays a critical role in arachidonate turnover in brain phospholipids and neutral lipids.	manoalide	26-35	phospholipase A2 group IB	Rattus norvegicus	65-81
9756393-20	1998	Results with the phospholipase A2 inhibitor, manoalide, suggest that glucocorticoid-induced protein synthesis (e.g. enhanced stimulation of lipocortin) does not play a role in the reduction of calcium influx.	manoalide	45-54	phospholipase A2, group IB, pancreas	Mus musculus	17-33
9593858-4	1998	This conclusion is supported by the findings that ET-1-induced AA release is inhibited by AACOCF3, quinacrine and manoalide, PLA2 inhibitors, but not by U-73122, a PLC inhibitor, or by RHC-80267, a diacylglycerol lipase inhibitor.	manoalide	114-123	endothelin 1	Homo sapiens	50-54
9449633-10	1998	Direct effects of SV and PLA2 on anterior pituitary ACTH secretion also were found to function in a concentration-related fashion (0.001-1 microg/ml), and the direct corticotropin-releasing activity of PLA2 was additive to those of CRH and arginine vasopressin; the corticotropin-releasing activity of both SV and PLA2 were partially reversed by the specific PLA2 inhibitor, manoalide.	manoalide	375-384	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	202-206
9449633-10	1998	Direct effects of SV and PLA2 on anterior pituitary ACTH secretion also were found to function in a concentration-related fashion (0.001-1 microg/ml), and the direct corticotropin-releasing activity of PLA2 was additive to those of CRH and arginine vasopressin; the corticotropin-releasing activity of both SV and PLA2 were partially reversed by the specific PLA2 inhibitor, manoalide.	manoalide	375-384	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	202-206
9449633-10	1998	Direct effects of SV and PLA2 on anterior pituitary ACTH secretion also were found to function in a concentration-related fashion (0.001-1 microg/ml), and the direct corticotropin-releasing activity of PLA2 was additive to those of CRH and arginine vasopressin; the corticotropin-releasing activity of both SV and PLA2 were partially reversed by the specific PLA2 inhibitor, manoalide.	manoalide	375-384	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	202-206
9232205-5	1997	On the other hand, 48/80-induced O2- generation was inhibited by phospholipase A2 inhibitors, such as arachidonyl trifluoromethyl ketone and manoalide.	manoalide	141-150	phospholipase A2 group IB	Rattus norvegicus	65-81
9403541-10	1997	Furthermore, inhibiting PAF production with AACOCF3, or manoalide, also inhibited LPS-induced Mphi TNF mRNA expression.	manoalide	56-65	tumor necrosis factor	Homo sapiens	99-102
9237867-5	1997	This conclusion is supported by the following findings: (1) ET-1-evoked AA release was inhibited by the PLA2 inhibitors dexamethasone, mepacrine and manoalide in a concentration-dependent manner.	manoalide	149-158	endothelin 1	Homo sapiens	60-64
9237867-5	1997	This conclusion is supported by the following findings: (1) ET-1-evoked AA release was inhibited by the PLA2 inhibitors dexamethasone, mepacrine and manoalide in a concentration-dependent manner.	manoalide	149-158	phospholipase A2 group IB	Homo sapiens	104-108
9080365-10	1997	The effect of muscarinic stimulation on the cotransporter can, however, be blocked by inhibitors of phospholipase A2 (4-bromophenacylbromide and manoalide), by a general inhibitor of arachidonic acid metabolism (5,8,11,14-eicosatetraynoic acid) and by specific inhibitors of the cytochrome P450 pathway (methoxsalen and ketoconazole).	manoalide	145-154	phospholipase A2 group IB	Rattus norvegicus	100-116
8843717-3	1996	Manoalide, an inhibitor for phospholipase A2, inhibited the ET-1-evoked response by 50% at 1 microM.	manoalide	0-9	phospholipase A2 group IB	Homo sapiens	28-44
8843717-3	1996	Manoalide, an inhibitor for phospholipase A2, inhibited the ET-1-evoked response by 50% at 1 microM.	manoalide	0-9	endothelin 1	Homo sapiens	60-64
7575673-11	1995	Scalaradial and to some extent manoalide were capable of blocking the IL-1 beta-induced expression of PHGS-2.	manoalide	31-40	interleukin 1 beta	Homo sapiens	70-79
8804438-12	1996	We have found that the inhibitors of PLA2, 4-bromophenacyl bromide and manoalide, completely blocked the increase of pH(i) and spreading of neutrophils upon adhesion to solid substrata.	manoalide	71-80	glucose-6-phosphate isomerase	Homo sapiens	117-122
8702436-1	1996	OBJECTIVE: To evaluate the effects of the phospholipase A2 (PLA2) inhibitor manoalide on cartilage degradation, stromelysin expression, and inflammatory cell accumulation in rabbits treated intraarticularly with recombinant human interleukin-1 alpha (rHuIL-1 alpha).	manoalide	76-85	phospholipase A2	Oryctolagus cuniculus	60-64
8702436-11	1996	Pretreatment with manoalide (0.3 mg/joint) significantly inhibited PLA2 activity in the synovial fluid, prevented the loss of proteoglycan from the condylar cartilage, and reduced proteoglycan levels in lavage fluids.	manoalide	18-27	phospholipase A2	Oryctolagus cuniculus	67-71
8702436-15	1996	CONCLUSION: These studies demonstrate that manoalide is a potent inhibitor of inflammation and cartilage catabolism, and suggest that PLA2 is involved in the pathophysiology of rHuIL-1 alpha-induced arthritis in rabbits.	manoalide	43-52	phospholipase A2	Oryctolagus cuniculus	134-138
8737743-0	1996	Effect of manoalide on human 5-lipoxygenase activity.	manoalide	10-19	arachidonate 5-lipoxygenase	Homo sapiens	29-43
8737743-1	1996	The marine natural product manoalide (MLD) has been described to inactivate phospholipase A2 (PLA2) from several sources as well as to inhibit synthesis of eicosanoids in human polymorphonuclear leukocytes (HPMNL).	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	76-92
8737743-1	1996	The marine natural product manoalide (MLD) has been described to inactivate phospholipase A2 (PLA2) from several sources as well as to inhibit synthesis of eicosanoids in human polymorphonuclear leukocytes (HPMNL).	manoalide	27-36	phospholipase A2 group IB	Homo sapiens	94-98
8732290-9	1996	The PLA2 inhibitors manoalide and scalaradial inhibited this enzyme activity in vitro in a concentration-dependent manner.	manoalide	20-29	phospholipase A2 group IB	Rattus norvegicus	4-8
7575673-2	1995	The marine natural products manoalide and scalaradial are potent anti-inflammatory agents that inactivate the enzyme phospholipase A2 (PLA2) in vitro.	manoalide	28-37	phospholipase A2 group IB	Homo sapiens	117-133
7575673-2	1995	The marine natural products manoalide and scalaradial are potent anti-inflammatory agents that inactivate the enzyme phospholipase A2 (PLA2) in vitro.	manoalide	28-37	phospholipase A2 group IB	Homo sapiens	135-139
7575673-5	1995	Manoalide and scalaradial (1-10 microM) inhibited LPS-induced endogeneous PGE2 production, reduced the LPS-induced PGHS activity, and reduced the expression of PGHS-2.	manoalide	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	160-166
7575673-8	1995	Manoalide and scalaradial also inhibited the release of IL-1 beta and TNF alpha from LPS-stimulated monocytes.	manoalide	0-9	interleukin 1 beta	Homo sapiens	56-65
7575673-8	1995	Manoalide and scalaradial also inhibited the release of IL-1 beta and TNF alpha from LPS-stimulated monocytes.	manoalide	0-9	tumor necrosis factor	Homo sapiens	70-79
7768638-6	1995	The accompanying c-myc up-regulation seems to be mediated by retinoic-acid-receptor-independent pathways involving membrane-associated phospholipases instead, because manoalide partly suppressed c-myc induction by ATRA but left constitutive c-myc expression unaffected.	manoalide	167-176	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
7768638-6	1995	The accompanying c-myc up-regulation seems to be mediated by retinoic-acid-receptor-independent pathways involving membrane-associated phospholipases instead, because manoalide partly suppressed c-myc induction by ATRA but left constitutive c-myc expression unaffected.	manoalide	167-176	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	195-200
7768638-6	1995	The accompanying c-myc up-regulation seems to be mediated by retinoic-acid-receptor-independent pathways involving membrane-associated phospholipases instead, because manoalide partly suppressed c-myc induction by ATRA but left constitutive c-myc expression unaffected.	manoalide	167-176	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	195-200
7981191-5	1994	Pretreatment of the cells with the phospholipase C and phospholipase A2 inhibitor manoalide (10 mumol/L) for 10 minutes at 37 degrees C completely abolished the calcium response, as did a 10-minute pretreatment with the inhibitor of actin polymerization, cytochalasin B (1 mumol/L).	manoalide	82-91	LOC104974671	Bos taurus	55-71
7829974-8	1995	This suggestion is also supported by the observation that manoalide, a standard inhibitor of phospholipase A2, similarly to U46619, inhibits beta-glucuronidase release from stimulated PMN.	manoalide	58-67	phospholipase A2 group IB	Homo sapiens	93-109
7829974-8	1995	This suggestion is also supported by the observation that manoalide, a standard inhibitor of phospholipase A2, similarly to U46619, inhibits beta-glucuronidase release from stimulated PMN.	manoalide	58-67	glucuronidase beta	Homo sapiens	141-159
7742810-4	1995	Various PL A2 inhibitors, such as manoalide, quinacrine and p-bromophenacyl bromide, suppressed the stimulatory release of lipoprotein lipase (LPL) activity from the fat pads by vanadate.	manoalide	34-43	lipoprotein lipase	Rattus norvegicus	123-141
7742810-4	1995	Various PL A2 inhibitors, such as manoalide, quinacrine and p-bromophenacyl bromide, suppressed the stimulatory release of lipoprotein lipase (LPL) activity from the fat pads by vanadate.	manoalide	34-43	lipoprotein lipase	Rattus norvegicus	143-146
7853352-10	1994	The PLA2 inhibitor, manoalide (a natural marine product), completely prevented PLA2 activation and cytotoxicity induced by TNF alpha.	manoalide	20-29	phospholipase A2, group V	Mus musculus	4-8
7853352-10	1994	The PLA2 inhibitor, manoalide (a natural marine product), completely prevented PLA2 activation and cytotoxicity induced by TNF alpha.	manoalide	20-29	phospholipase A2, group V	Mus musculus	79-83
7853352-10	1994	The PLA2 inhibitor, manoalide (a natural marine product), completely prevented PLA2 activation and cytotoxicity induced by TNF alpha.	manoalide	20-29	tumor necrosis factor	Mus musculus	123-132